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Abstract
Introduction: Autoimmune inflammation is a characteristic feature of rheumatoid arthritis (RA) and other autoimmune
diseases. In the natural course of human autoimmune diseases, it is rather difficult to pinpoint the precise timing of the
initial event that triggers the cascade of pathogenic events that later culminate into clinically overt disease. Therefore, it
is a challenge to examine the early preclinical events in these disorders. Animal models are an invaluable resource in
this regard. Furthermore, considering the complex nature of the pathogenic immune events in arthritis, microarray
analysis offers a versatile tool to define the dynamic patterns of gene expression during the disease course.
Methods: In this study, we defined the profiles of gene expression at different phases of adjuvant arthritis (AA) in
Lewis rats and compared them with those of antigen mycobacterial heat shock protein 65 (Bhsp65)-tolerized
syngeneic rats. Purified total RNA (100 ng) extracted from the draining lymph node cells was used to generate
biotin-labeled fragment cRNA, which was then hybridized with an oligonucleotide-based DNA microarray chip.
Significance analysis of microarrays was used to compare gene expression levels between the two different groups
by limiting the false discovery rate to < 5%. Some of the data were further analyzed using a fold change ≥2.0 as
the cutoff. The gene expression of select genes was validated by quantitative real-time PCR.
Results: Intriguingly, the most dramatic changes in gene expression in the draining lymphoid tissue ex vivo were
observed at the preclinical (incubation) phase of the disease. The affected genes represented many of the known proteins
that participate in the cellular immune response. Interestingly, the preclinical gene expression profile was significantly
altered by a disease-modulating, antigen-based tolerogenic regimen. The changes mostly included upregulation of several
genes, suggesting that immune tolerance suppressed disease by activating disease-regulating pathways. We identified a
molecular signature comprising at least 12 arthritis-related genes altered by Bhsp65-induced tolerance.
Conclusions: This is the first report of microarray analysis in the rat AA model. The results of this study not only
advance our understanding of the early phase events in autoimmune arthritis but also help in identifying potential
targets for the immunomodulation of RA.
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Introduction
Rheumatoid arthritis (RA) is a major global health pro-
blem that imposes a heavy socioeconomic burden on
society [1,2]. The disease is characterized by chronic
inflammation of the synovial joints, often leading to
physical deformities [3,4]. The precise etiology of RA is
not known. It is a multifactorial disease involving both
genetic and environmental components [3,5,6]. The
joint pathology results from concerted action of many
different cell types (macrophages, T cells, B cells, fibro-
blasts, and so on) and diverse cellular and molecular
pathways [3,4]. There is meager information about the
early phase (preclinical) inflammatory and immune
events that lead to the initiation of the disease process.
There also is a need for reliable biomarkers of the
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efficacy but less toxicity. Thus, there is an urgent need
to comprehensively examine and define the complex
pathogenesis of RA with the hope of identifying new
targets for treatment as well as monitoring the disease
process. However, the genetic heterogeneity of human
populations and the limitation of obtaining preclinical
(incubation phase) biological samples from RA patients
pose formidable challenges. In this regard, experimental
models of human RA offer an invaluable resource in
examining some of the above-mentioned critical issues
that cannot be directly addressed in RA patients.
Adjuvant-induced arthritis (AA) is a well-studied model
of RA that has been used extensively to study the patho-
genesis of RA as well as to test new, potentially antiar-
thritic compounds [7-12]. AA can be induced in the
inbred Lewis (LEW) (RT.1
l) rat by subcutaneous immuni-
zation with heat-killed Mycobacterium tuberculosis H37Ra
(Mtb), and it shares several features with human RA
[13,14]. Furthermore, different phases of arthritis (incuba-
tion, onset, peak and recovery) during the course of AA
are clearly identifiable [15,16], making it a suitable model
for the study of preclinical (incubation phase) events in
the disease course. Because of the genetic homogeneity
and controlled disease induction, AA is an appropriate
model for examining early pathogenetic events of autoim-
mune arthritis and their modulation by therapeutic regi-
mens such as immune-based approaches.
Antigen-induced tolerance is one of the immunomo-
dulatory approaches actively being explored for the con-
trol of autoimmune diseases, including RA [17-20].
Studies by others [10-12,21] and us [22,23] in the AA
model of RA have documented the efficacy of a variety
of tolerogenic approaches for the prevention as well as
the treatment of arthritis. For example, we have pre-
viously shown that tolerization of LEW rats with soluble
mycobacterial heat shock protein 65 (Bhsp65), which
represents one of the major disease-related antigens in
AA, affords protection against subsequent induction of
AA [22]. However, despite the significant advances in
the field of immune tolerance [24], the molecular basis
of the antiarthritic effects of a tolerogenic regimen is
not yet fully defined. A system-wide analysis of the early
phase events in arthritis and the molecular targets of an
arthritis-protective tolerogenic regimen would signifi-
cantly advance our understanding and management of
the arthritogenic processes.
Microarray analysis offers a comprehensive tool with
which to simultaneously examine thousands of genes
relating to diverse pathways mediating biochemical,
molecular, immunological and pathological events in the
course of a disease. The readouts, consisting of
increased, decreased or unchanged expression of a large
panel of genes, offer insights into the concurrent
changes in multiple interrelated pathways at a given
time point in the healthy or diseased state. With the
completion of the sequencing of the genomes of human,
mouse and rat, the results of microarray analyses can be
further extended to comparative analyses of homologous
genes of interest. However, the early phase events are
not easy to study in RA patients, and microarray gene
expression profiling of rats with AA has not previously
been reported. Therefore, we undertook this important
and timely study of gene expression analysis in AA.
In this study, we examined the gene expression pro-
files of the draining lymph node cells (LNCs) of Mtb-
immunized LEW rats and compared them with those of
antigen (Bhsp65)-tolerizedo ra n t i g e n - n a ï v er a t s .T h e
induction of AA in LEW rats following Mtb injection
involves the priming of potentially pathogenic T cells
within the draining lymph nodes [14,25-28], and these T
cells then migrate into the target organ, the joints, to
initiate the development of arthritis. Conceivably, there
are dynamic alterations in the relative frequency and
activity of arthritogenic vs. disease-regulating T-cell sub-
sets within the draining lymph nodes during the disease
course. Furthermore, the pathogenesis of arthritis
i n v o l v e sn o to n l yl y m p h o i dc e l l sb u ta l s om y e l o i d - l i n e -
age cells [29-31]. Therefore, to fully understand the
expression of disease-relevant genes within the draining
lymph nodes in vivo during the course of AA, we tested
bulk LNCs instead of purified T cells alone.
We hypothesized that the early (incubation) period
following Mtb injection of LEW rats is a critical phase
of the disease (AA) during which the host immune sys-
tem is modulated and steered toward arthritis induction.
Furthermore, immune interventions such as antigen-
induced tolerance, which prevent subsequent develop-
ment of AA, would significantly influence the early
phase molecular events. In this study, we first tested the
unmodified ex vivo gene expression profiles at different
phases of the disease (AA) in LEW rats. Thereafter we
focused on the incubation phase of AA to determine the
antigen (Bhsp65)-induced gene expression and how it is
modulated by an immunomodulatory Bhsp65-induced
tolerance approach. We identified a molecular signature
of at least 12 differentially expressed genes (DEGs) that
characterize the state of Bhsp65-induced tolerance. We
believe that the results of our study will not only
improve the attributes of the AA model per se but also
provide useful insights into both the pathogenetic pro-
cesses in RA and potential immunomodulatory targets
for controlling this disease.
Materials and methods
Induction and evaluation of adjuvant arthritis
Male Lewis (LEW/SsNHsd) (LEW) (RT-1
1)r a t s ,f i v et o
six weeks old, were obtained from Harlan Sprague
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dited animal facility at the University of Maryland at
Baltimore (UMB). All animal handling and experimental
work was carried out in accordance with the National
Institutes of Health guidelines for animal welfare, and
t h es t u d yw a sa p p r o v e db yt h eI n s t i t u t i o n a lA n i m a l
Care and Use Committee at our institution. The animals
were acclimated to the holding room for at least three
days before the initiation of our experimental work. AA
was induced in each LEW rat on day 0 by immunizing
them subcutaneously at the base of the tail with 2 mg of
heat-killed Mtb (Difco, Detroit, MI, USA) emulsified in
200 μL of mineral oil (Sigma-Aldrich, St Louis, MO,
USA). The development of arthritis and its severity were
evaluated regularly by examination of all four paws for
signs of arthritis and graded on a scale from 0 to 4 per
paw on the basis of redness, swelling and induration.
Arthritis appeared by about days 10 to 12 after Mtb
injection. The disease severity reached its peak by days
19 to 21, followed by spontaneous regression of inflam-
mation. In this study, we selected specific time points in
the course of AA that represent different phases, as fol-
lows: day 7, incubation (Inc) phase; day 21, peak (Pk)
phase; and day 25, recovery (Rec) phase. Naïve (Nv) rats
without any Mtb immunization served as the baseline
controls. Three animals per group were killed at each of
the above time points for LEW rats, and draining lymph
nodes (superficial inguinal, paraaortic and popliteal)
were harvested.
Antigen-induced immune tolerance
LEW rats were injected intraperitoneally on alternate
days with soluble Bhsp65 at a dose of 200 μgf o rat o t a l
of three injections [22]. Nine days after the first injec-
tion the rats were immunized subcutaneously with Mtb
(day 0) for the induction of AA. These Bhsp65-tolerized,
Mtb-immunized rats were killed at the Inc phase of AA,
and their draining lymph nodes were harvested for
further testing.
Antigenic restimulation of lymph node cells in vitro
The draining LNCs of LEW rats (with or without the
tolerogenic Bhsp65 pretreatment) were collected on day
7 after Mtb immunization. These LNCs were cultured at
37°C for 24 hours in a six-well plate (5 × 10
6 cells/well)
in serum-free HL-1 medium (Lonza, Walkersville, MD,
USA) with or without Bhsp65 (5 μg/ml). Thereafter the
cells were processed for RNA extraction.
Total RNA extraction and GeneChip hybridization
Total RNA was extracted from LNCs using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions. RNA was purified with the
RNeasy Mini Kit (Qiagen Ltd, Crawley, UK). RNA
concentration was determined spectrophotometrically
(260/280 nm, 260/230 nm) using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies/Thermo
Scientific, Wilmington, DE, USA). The quality of RNA
was further assessed using the RNA 6000 Nano LabChip
Kit (Agilent Technologies Inc, Palo Alto, CA, USA) and
the Agilent 2100 Bioanalyzer. The RNA integrity num-
ber (mean ± SD) of the RNA isolated from freshly har-
vested and unstimulated LNCs was 9.61 ± 0.26 with a
coefficient of variation (CV) of 2.7%, whereas that of the
RNA extracted from LNCs cultured in vitro with or
without Bhsp65 was 8.0 ± 0.5 with a CV of 6.3%. Total
RNA (100 ng) was used as the input for the amplifica-
tion and generation of biotin-labeled fragment cRNA for
expression analysis using the Affymetrix kit (Genechip
WT Sense Target Labeling and Control Reagents)
according to the protocol supplied by the manufacturer
(Affymetrix Inc, Santa Clara, CA, USA). Labeled cRNA
was hybridized with an oligonucleotide-based DNA
microarray (GeneChip Rat Gene 1.0 ST Array; Affyme-
trix) for whole-transcript coverage analysis. This micro-
array platform contains 700,000 unique 25-mer
oligonucleotide features (spots) representing 27,342
Entrez Gene IDs. Hybridization on GeneChip Fluidics
Station 450, scanning and image processing on Gene-
Chip Scanner 3000 7G and preliminary data manage-
ment with Affymetrix Microarray Suite version 5.0
software (all manufactured by Affymetrix, Inc) were per-
formed at the Genomics Core Facility at UMB in accor-
dance with the manufacturer’s guidelines.
Microarray data analysis
Affymetrix.cel files were uploaded to the Affymetrix
Expression Console™ 1.1, checked for quality and then
corrected for background. The data were normalized,
and the median was polished using a robust multiarray.
All data were logarithmically transformed prior to statis-
tical analysis. Thereafter significance analysis of microar-
rays was used to compare gene expression levels
between two different groups (three independent experi-
ments, that is, three chips per group, biological repli-
cates) by limiting the false discovery rate (FDR) to < 5%.
With this FDR, DEGs [32] were identified. Some of the
data were further analyzed using a ≥2.0-fold change as
the cutoff. A heat map showing changes in the expres-
sion levels (fold changes) of representative genes was
generated in the R software program with the package
“gplots.” Specifically, the fold changes in expression
levels derived from log2 scales were organized with
Expression Profiler software using the average linkage
hierarchical clustering method, with distance determined
by the correlation. Further analysis was performed to
identify the biological processes involving the DEGs
using the UniProt databases [33]. Enrichment analysis
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Ontology (GO) and KEGG databases [34,35], which
revealed themes indicative of inflammatory disease,
immune response, antigen processing and presentation,
and so on. The microarray experimental plan and data
analysis in this study are in accordance with the
MIAME (minimum information about a microarray
experiment) guidelines [36]. The microarray data pre-
sented in this manuscript have been deposited in a pub-
lic repository, the Gene Expression Omnibus (GEO)
[GEO:GSE31314].
Quantitative real-time polymerase chain reaction for
measuring gene expression
RNA extracted from LNCs tested ex vivo or after in
vitro restimulation was used to validate microarray data.
Column-purified total RNA was reverse-transcribed
u s i n gt h ei S c r i p tc D N AS y n t h e s i sK i t( B i o - R a dL a b o r a -
tories, Hercules, CA, USA) with oligo(dT) primers as
described by the manufacturer. cDNA templates for
quantitative real-time PCR (qPCR) were prepared by
diluting them 1:10 and then amplified by using specific
primers (Sigma) in SYBR Green PCR Master Mix (AB
Applied Biosystems, Warrington, UK) on the LightCy-
cler Instrument (Roche Applied Science, Indianapolis,
IN, USA). Expression of the following genes was ana-
lyzed: IFN-g, IL-10, IL-17, Nos2, Ccr5, Socs1 and Socs3.
The levels of mRNA were normalized to HPRT (hypox-
anthine phophoribosyltransferase) controls. The cycle
threshold (Ct) values, corresponding to the PCR cycle
number at which fluorescence emission reached a
threshold above baseline emission, were determined,
and the relative mRNA expression was calculated using
the 2-
ΔΔCt method [16]. The Bland-Altman method [37]
was used to assess the agreement in gene expression
obtained by using microarrays and qPCR for the
selected genes.
Results
Gene expression profiles at different phases during the
natural course of adjuvant arthritis in LEW rats
One of the goals of this study was to examine the ex
vivo gene expression profiles of the draining LNCs of
arthritic LEW rats at different phases of the disease,
namely, the Inc, Pk and Rec phases. Nv LEW rats served
as the baseline nonarthritic controls. The choice of ex
vivo testing of LNCs was made to obtain a snapshot of
the unperturbed gene expression profiles closely depict-
ing the in vivo gene expression profiles. Three pairwise
comparisons of gene expression patterns were per-
formed: Inc-Nv, Pk-Nv and Rec-Nv. The results showed
distinct gene expression profiles at different phases of
AA (Figures 1 and 2A). As per our prediction, the most
significant changes in gene expression were observed at
the Inc phase, before the signs of arthritis appeared,
instead of at the Pk phase of AA (Figures 1 and 2). This
was evident by both the number and the level of expres-
sion of DEGs. Rats at the Inc phase had no overt signs
of clinical arthritis (preclinical AA). A comparison of
Inc rats with NV rats (Inc-Nv) revealed a relatively large
number of DEGs. All DEGs (322 of the 29,214 screened
probe sets) showed upregulation at the Inc period of
AA compared to the baseline level (Figure 2A). In con-
trast, as described below, most of the genes were found
to be downregulated during the Pk and Rec phases to
the level of Nv rats (Figures 1 and 2A). Fewer genes (15
genes) maintained expression at a high level during the
whole disease course (Inc through Rec phase). The
major functional groups of DEGs at the Inc phase of
AA are given in Tables 1 and 2.
To monitor the progression of the disease after the
onset of AA, we analyzed genes that were differentially
expressed in LNCs at the time of acute disease (Pk) and
during recovery from acute arthritis (Rec), with each
phase compared to that of the Nv rats. Both Pk and Rec
phases of AA were associated with the expression of a
relatively small number of genes (Figures 1, 2A and 2C).
In the Pk phase, 31 genes were upregulated but 27 were
downregulated, whereas in the Rec phase, 28 genes
showed increased expression but 7 displayed reduced
expression.
The relationship of the genes expressed at different
phases of AA is shown in a dendrogram derived from
cluster analysis (Figure 2B) and in a Venn diagram (Fig-
ure 2C). As depicted in Figure 2C, only 15 genes
(Cd163, Klrc1, Lgmn, Tnfrsf4, Il1r2, Ifitm1, Il23r, Ccr4,
C p d ,L i p g ,R a r r e s 1 ,O l f m 1 ,M t 1 aand two undefined
genes) each were differentially upregulated in all three
phases of the disease (Inc, Pk and Rec); 23 genes each
were differentially expressed both at the Inc phase and
during the Pk phase; 16 genes each were active in both
the Pk and Rec phases; and 18 genes each shared a
common expression pattern in the Inc and Rec phases
of AA.
S i n c eal a r g en u m b e ro fD E G sw e r er e v e a l e da tt h e
early preclinical phase (Inc), which is devoid of any clin-
ical signs of arthritis, we propose that these genes are of
significance in the initiation and subsequent progression
of AA. To gain insight into the biological processes that
might be influenced by DEGs in the Inc phase, we
assigned the 322 early genes to separate groups accord-
ing to their corresponding protein function and Gene
Ontology classification (Table 1). We found that the
DEGs at the Inc phase included the genes encoding the
proteins related to cell proliferation, immune activity,
inflammation, cell migration (including chemokines,
chemotaxis and cell adhesion) and proteolysis, as well as
certain metabolic and signal pathways.
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of AA, we performed qPCR on a set of randomly
selected genes among those relevant to arthritis: IFN-g,
IL-10, IL-17, Nos2, CCR5, Socs1 and Socs3.T h eB l a n d -
Altman plots (Figure 2D) suggest that all expression
levels are within the 95% confidence limits for agree-
ment, suggesting reasonable agreement of the expression
obtained with the two methods.
As the Inc phase of AA revealed the most marked dif-
ferences in gene expression, we chose this phase to
further study the gene expression profiles of Bhsp65-res-
timulated LNCs of Mtb-immunized LEW rats and
Bhsp65-tolerized, Mtb-immunized LEW rats.
Antigen (mycobacterial heat shock protein 65)-induced
gene expression profile of LEW rats in the preclinical
phase of adjuvant arthritis
The precise autoantigen that induces immune disorder
in RA remains unknown. Bhsp65 represents an impor-
tant disease-related antigen in arthritis [39,40]. Several
studies have revealed that rats with AA [7,12,27,40,41]
and patients with RA [40,42-47] develop T-cell
responses as well as antibody responses to heat shock
protein 65. Furthermore, preventive or therapeutic inter-
ventions that suppress AA also alter immune responses
to Bhsp65 [22,40,48]. In this context, we examined the
expression profile of Bhsp65-induced genes in the drain-
ing LNCs of LEW rats in the Inc phase of AA. The
LNCs harvested from LEW rats on day 7 after Mtb
immunization were cultured for 24 hours with or with-
out Bhsp65. The total RNA isolated from these LNCs
was subjected to microarray analysis. The results are
shown in Figures 3A, C and 5A. A total of 61 DEGs (41
upregulated and 20 downregulated) were found to be
significantly influenced by Bhsp65. These genes showing
altered expression encoded the leukocyte-specific mar-
kers and receptors, cytokines and receptors, chemokines
and receptors, adhesion molecules, components of the
complement cascade, molecules involved in antigen pro-
cessing and presentation, regulators of angiogenesis,
transcription factors and signal transduction-related
molecules (Tables 2 and 3). Not surprisingly, the
Bhsp65-induced gene expression profile mostly rein-
forced the immune-based and inflammatory nature of
AA. The expression levels of important arthritis-related
genes in these preclinical arthritis rats are given in
Table 3.
Gene expression profile of mycobacterial heat shock
protein 65-tolerized LEW rats and its comparison with
that of LEW rats in the preclinical phase of adjuvant
arthritis
We described above that Bhsp65 represents an impor-
tant disease-related antigen in LEW rats with AA
[7,12,27,40,41]. Accordingly, Bhsp65 also offers an
attractive antigen for use in the immunomodulation of
AA [7,10-12]. In fact, induction of immune tolerance
against Bhsp65 can successfully downmodulate the
onset and progression of AA [22]. However, the
Figure 1 Gene expression profiles of lymphoid cells ex vivo at
different phases of adjuvant arthritis in Lewis rats. Shown is a heat
map representation of differentially expressed genes (DEGs) at the
indicated phases of adjuvant arthritis (AA) in Lewis (LEW) (RT.1
l)r a t s .
Red denotes increased expression, and green indicates reduced
expression compared to the baseline naïve (Nv) controls. At each
phase of AA, total RNA was extracted from the draining ex vivo lymph
node cells and tested using a microarray gene chip. Approximately
370 DEGs are shown. Inc, incubation; Pk, peak; Rec, recovery.
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the genes that might be involved in the modulation of
AA by Bhsp65-induced tolerance, and also to identify
additional potential autoimmune targets for therapy,
we compared the mRNA expression profile of LNCs
from Bhsp65-pretreated, Mtb-injected LEW rats after
seven days of disease induction (Figure 4B) with that
of the Mtb-immunized LEW rats in the Inc phase of
AA (Figure 4A). For each group of rats, we compared
the profile of LNCs restimulated by Bhsp65 in vitro
with that of LNCs cultured in medium alone (baseline
level). The Bland-Altman plots (Figure 5B) suggest that
all expression levels are within the 95% confidence
limits for agreement, suggesting reasonable agreement
of the expression levels obtained with the two
methods.
Figure 2 Relationship of the differentially expressed genes at different phases of adjuvant arthritis. (A) The number of differentially
expressed genes (DEGs) at different phases of adjuvant arthritis (AA) compared to the rats in the naïve (Nv) state. (B) Dendrogram visualized
using TreeView software [38] representing the relationship between DEGs at different phases of AA. (C) Venn diagram showing the number of
DEGs and their overlap in the three data sets: Inc/Nv, Pk/Nv and Rec/Nv (Inc, incubation; Nv, naïve; Pk, peak; Rec, recovery). (D) Bland-Altman
plots. The x-axis represents the average fold change of each sample measured by quantitative real-time PCR (qPCR) and microarrays. The y-axis is
the difference in fold change calculated by qPCR measurements minus the microarray measurements for each sample. The solid line (y = 0.652)
is the mean difference in fold change of all the samples. The two dotted lines represent two standard deviations away from the mean
difference.
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LNCs in medium alone) in Bhsp65-tolerized LEW rats
and LEW rats with preclinical AA showed little differ-
ence (four DEGs only), there were substantial
differences in DEGs (Bhsp65 restimulation vs. medium
in vitro) in Bhsp65-restimulated LNCs of these two
groups (Figures 4C and 5A). The total DEGs numbered
591 for the Bhsp65-tolerized group compared to 61 for
the preclinical AA group. Furthermore, the upregulated
genes comprised 98% (579 of 591 genes) of DEGs in the
Bhsp65-tolerized rats (Figures 4B and 5A) but only
67.2% (41 of 61 genes) of DEGs in the rats with preclini-
cal AA (Figures 4A and 5A). Interestingly, the upregu-
lated DEGs in Bhsp65-tolerized rats reflect a spectrum
of immune markers and pathways, including T-cell cost-
imulatory molecule, cytokines and receptors, chemo-
kines and receptors, and angiogenesis (Tables 2 and 3).
In comparison with preclinical arthritis rats, Bhsp65-tol-
erized rats showed downregulation of Th1 and Th17
(proinflammatory response) and of other mediators of
inflammation and angiogenesis, but upregulation of IL-
10 (anti-inflammatory and immunoregulatory). At least
12 arthritis-related DEGs constitute the molecular signa-
ture of Bhsp65-induced tolerance (Table 3). These genes
encode the following proteins: CD86, IFN-a-inducible
protein 27- like 1, IL-1b, lymphotoxin-a, SOCS3, IL-10,
IL-33, IL-17 precursor, IL-17F, IL-22, CXCR7 and
VEGF-A.
Table 1 The major functional groups represented by 322 differentially expressed genes at the incubation phase of
adjuvant arthritis in Lewis rats
a
Functional group Number
(%)
Innate immunity 19 (5.9%)
Cell markers, innate immune response, complement
Cell-mediated adaptive immune response and effector functions 23 (7.1%)
Stress protein-related and other autoantigens, antigen processing and presentation, T cell costimulation,
cytokines and cytokine receptors, activators and regulators
Humoral immunity 8 (2.5%)
Cell proliferation 113 (35.1%)
DNA synthesis, replication, repair, tRNA processing, transcription, translation, cell
cycle and cellular components
Cell migration 24 (7.4%)
Adhesion molecules, integrins, chemokines and receptors, cell migration-related
Angiogenesis 2 (0.6%)
Oxygen metabolism related to pathogenesis of arthritis 11 (3.4%)
Transporters of oxygen, electrons, reactive oxygen species, cellular response to oxygen level and oxidation reduction
Articular damage 4 (1.2%)
Metabolism 25 (7.7%)
Glucose metabolism, proteolysis, peptide or amino acid transporter and protein metabolism, lipid metabolism and other metabolic
processes
Signal transduction and signaling pathways 16 (5.0%)
Phosphorylation and dephosphorylation, kinase activity and regulation, signal
transduction and regulation, G protein-coupled receptor signaling pathway and others
Tumor- and disease-related 8 (2.5%)
Neuron development, neurotransmitters and neuropeptide signaling 4 (1.2%)
Ion binding and transporters, binding activity 7 (2.1%)
Undefined function and unnamed genes 59 (18.3%)
aDEG: differentially expressed gene; tRNA: transfer RNA. “Immune activity” group includes DEGs in the first three categories: 50 (15.5%).
Table 2 Summary of differentially expressed genes in the
lymph node cells of different groups of Lewis rats tested
ex vivo and in vitro
a
DEGs, n (%)
Characteristics Upregulation Downregulation Total
Ex vivo
Inc/Nv 322 (100%) 0 (0%) 322
Pk/Nv 31 (53.4%) 27 (46.6%) 58
Rec/Nv 28 (80%) 7 (20%) 35
In vitro
Preclinical arthritis rats 41 (67.2%) 20 (32.8%) 61
Preclinical Bhsp65-
tolerized rats
579 (98%) 12 (2%) 591
aDEG: differentially expressed gene. “Ex vivo“ group shows DEGs in lymph node
cells (LNCs) at incubation (Inc), peak (Pk) or recovery (Rec) phase compared to
naïve (Nv) state; “in vitro“ group shows DEGs induced by mycobacterial heat
shock protein 65 (Bhsp65) compared to baseline control (LNCs cultured in
medium alone). In Bhsp65-tolerized group, only 76 (12.86%) of the 579 DEGs
were related to immune activity (innate immunity, cell-mediated immunity and
humoral immunity). The major groups comprised genes relating to cellular
proliferation 127 (21.5%) and metabolism 137 (23.2%).
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a downmodulatory effector response in which activated
immune system events are suppressed. Accordingly, it is
presumed that the levels of expression of several genes
associated with immune effector pathways would be
downregulated in Bhsp65-tolerized rats compared to
preclinical arthritis rats. In this context, our results
showing that the number of genes with upregulated
expression levels is much higher in Bhsp65-tolerized
rats than those in preclinical arthritis rats (Tables 2 and
3) indicate that the state of immune tolerance is an
active process involving enhanced gene expression. We
Figure 3 Comparative gene expression profiles of antigen-stimulated lymph node cells in vitro and unstimulated lymph node cells ex
vivo in preclinical arthritis rats. A heat map representation of the DEGs of LNCs of different groups of rats is shown. (A) LNCs harvested from
Lewis (LEW) (RT.1
l) rats on day 7 after heat-killed Mycobacterium tuberculosis H37Ra (Mtb) injection (preclinical AA) were cultured in vitro for 24
hours with or without mycobacterial heat shock protein 65 (Bhsp65). (B) LNCs harvested from naïve (Nv) rats and from rats with preclinical
arthritis (Inc) were tested ex vivo without culture in vitro. The results were compared as indicated in the figure. (B) Part of Figure 1 included for
easy comparison with (A). Red represents upregulated expression, and green indicates downregulated expression. (C) Venn diagram showing
the relationship of DEGs in LNCs tested ex vivo versus Bhsp65-restimulated LNCs. DEG: differentially expressed gene; LNC: lymph node cell; Med:
medium.
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that can induce attenuation of pathogenic immune
responses. For example, enhanced expression of genes
encoding the proteins involved in immunoregulatory
activities (for example, IL-10) might explain the
observed profile of gene expression.
Discussion
On the basis of using the rat adjuvant-induced arthritis
model of human RA and microarray technology in this
study, we describe the gene expression profiles of
arthritic LEW rats at different phases of the disease as
well as the modulation of gene expression by a tolero-
genic disease-protective regimen employing the disease-
related antigen Bhsp65. We tested the draining LNCs of
arthritic rats ex vivo as well as after their restimulation
with Bhsp65. We extended this analysis to the LNCs of
LEW rats administered a tolerogenic challenge of
Bhsp65, which results in a significant reduction in the
severity of arthritis [22]. The criteria for a positive gene
expression response (for example, FDR set < 5% and
fold increase) are outlined in the Materials and methods
section.
Gene expression profiles during the natural course of
adjuvant arthritis in LEW rats
The natural course of AA in LEW rats is discernible in
distinct phases: Inc, Pk and Rec. We compared the ex
vivo gene expression profile of LNCs at each of these
phases with that of Nv LEW rats, which served as the
baseline. Our results reveal that the maximum changes
in gene expression, both quantitatively and qualitatively,
were observed at the Inc phase of arthritis instead of the
Pk phase of the disease. In fact, most of the genes
showed significantly reduced expression at the Pk and
Rec phases compared to the Inc phase. As the LNCs
were tested ex vivo directly after being harvested from
the rats, the observed patterns of gene expression likely
represent the natural in vivo expression profiles. These
results show that the Inc phase of AA is a critical and
very active stage of the disease in terms of changes in
the expression of genes encoding a large number of pro-
teins that participate in the induction of arthritis. The
Inc phase of AA is equivalent to the preclinical phase of
human RA. Therefore, our results are of significance in
advancing our understanding of the initiation of the dis-
ease process. Furthermore, as yet there is no reliable
biomarker that can predict the induction of RA in a
given individual. On the basis of our results described
above, we are hopeful that similar studies in RA patients
might lead us to discover the much-needed biomarkers
of diagnostic and prognostic value. In addition, as
described below, such analysis would also be of great
Figure 5 Comparison of the gene expression patterns of
mycobacterial heat shock protein 65-tolerized rats and rats
with preclinical adjuvant arthritis. (A) DEGs in LNCs of
mycobacterial heat shock protein 65 (Bhsp65)-tolerized rats (T) and
rats with preclinical AA (P) are shown. Also shown are DEGs shared
(S) between the two groups (data derived from Figure 4). (B) Bland-
Altman plots. The x-axis represents the average fold change of each
sample measured by quantitative real-time PCR (qPCR) and
microarrays. The y-axis is the difference in fold change calculated by
qPCR measurement minus microarray measurements for each
sample. The solid line (y = 14.89) is the mean difference in fold
change of all the samples. The two dotted lines represent two
standard deviations from the mean. AA: adjuvant arthritis; DEG:
differentially expressed gene; LNC: lymph node cell; med: medium.
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Page 9 of 16utility in defining the molecular changes induced by an
immunomodulatory (preventive) regimen for arthritis.
The DEGs at the Inc phase were related to cell prolif-
eration, immune activity, inflammation, cell migration
(including chemokines, chemotaxis and cell adhesion)
and proteolysis (Table 1). The most abundantly repre-
sented genes were those associated with cell prolifera-
tion (113 genes, 35%); however, barely any of these
genes were found to be expressed in the later phases of
AA. The immune activity genes, including both innate
and adaptive immune responses, were highly repre-
sented at the early phase (Inc; 42 genes, 13%), but were
much less abundant at the Pk phase (19 genes) and the
Rec phase (10 genes). The immune activity genes with a
significant change in expression levels included those
encoding the immune cell markers CD14, CD163 and
CD163l1; Th1 and Th17 cytokines and cytokine recep-
tors; immunoglobulins; and complement components.
All of these are relevant for promoting inflammation
and immune damage. Also, upregulated were the genes
for IL-1 receptor type II (Il1r2), IL-1 receptor antagonist
(Il1ra) and suppressor of cytokine signaling 3 (Socs3).
The increased expression of some of the anti-inflamma-
tory genes, along with the enhanced expression of many
proinflammatory genes, most likely reflects the attempt
of the host to counter the emerging inflammation.
The infiltration of inflammatory cells into the joints
is believed to initiate the activation of synovial cells
and subsequent hyperplasia of the synovial lining,
which eventually leads to destruction of the cartilage
and bone in arthritic joints [3,49,50]. Therefore, the
migration of immune cells into the joints is a critical
trigger for disease induction in arthritis. We found
altered expression of 24 genes (7.5%) that facilitated
cell migration at the Inc phase, but only 3 at Pk and
Rec phases combined. These results suggest that cell
Table 3 The comparative gene expression profiles of preclinical arthritis rats and Bhsp65-tolerized rats for the subsets
of genes that play a role in the pathogenesis of arthritis
a
Fold change (compared to baseline)
Gene symbol Gene name Preclinical arthritis rats Bhsp65-tolerized rats
Costimulatory molecule
Cd86 CD86 molecule # +2.06*
Cytokine or cytokine receptor
Ifi47 Interferon g-inducible protein 47 +2.44* +2.37*
Ifi27l1 Interferon a-inducible protein 27-like 1 +2.14* #
Il1a Interleukin 1a +4.61* +3.21*
Il1b Interleukin 1b # +3.05*
Lta Lymphotoxin a (TNF superfamily, member 1) # +2.10*
Socs1 Suppressor of cytokine signaling 1 +3.67* +3.14*
Socs3 Suppressor of cytokine signaling 3 # +2.44*
Ifng Interferon g +10.00* +9.09*
Il12rb2 Interleukin 12 receptor b2 +4.08* +3.89*
Il10 Interleukin 10 # +2.07*
Il33 Interleukin 33 -2.50* #
LOC301289 Similar to interleukin 17 precursor (IL-17) +16.74* #
Il17f Interleukin 17F +7.86* #
RGD1561292 Interleukin 22 +7.26* #
Chemokine/receptor
Cxcl10 Chemokine (C-X-C motif) ligand 10 +8.02* +8.15*
Ccr5 Chemokine (C-C motif) receptor 5 +2.22* +2.50*
Cxcr7 Chemokine (C-X-C motif) receptor 7 -2.47* #
Angiogenesis
Wars Tryptophanyl RNA synthetase +2.29* +2.17*
Vegfa Vascular endothelial growth factor A # +2.21*
Nos2 Nitric oxide synthase 2, inducible +7.83* +4.77*
Others
Bst2 Bone marrow stromal cell antigen 2 +2.90* +3.04*
Slc7a2 Solute carrier family 7 (cationic amino acid transport) +4.98* +4.15*
aBhsp65: mycobacterial heat shock protein 65. The genes listed were selected using false discovery rate < 5% and ≥2-fold change as the cutoff; +, upregulation;
-, downregulation (- number); *significant compared to the corresponding baseline expression; #not significant compared to the corresponding baseline
expression.
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Page 10 of 16migration into the joints is facilitated in the Inc period,
which then triggers the inflammatory events evident at
the onset of AA. In addition, surprisingly, the numbers
of genes encoding the extracellular matrix degradation-
related proteins that are relevant to bone destruction
a r em o r ea b u n d a n ti nt h ee a r l y( I n c )p h a s ec o m p a r e d
to the Pk and Rec phases of AA. These genes encode
latexin, matrix metallopeptidase 14 (Mmp14) and
membrane metalloendopeptidase. Mmp8,a n o t h e r
important gene involved in the pathogenesis of bone
damage, was significantly upregulated in the Pk
through Rec phases.
Figure 4 Comparative gene expression profiles of antigen-stimulated lymph node cells of mycobacterial heat shock protein 65-
tolerized rats versus preclinical arthritis rats. A heat map representation of the DEGs induced by mycobacterial heat shock protein 65
(Bhsp65) in LNCs is shown. (A) LNCs harvested from Lewis (LEW) (RT.1
l) rats on day 7 after heat-killed Mycobacterium tuberculosis H37Ra (Mtb)
injection (preclinical AA) were cultured in vitro for 24 hours with or without Bhsp65. (B) LNCs of Bhsp65-tolerized rats were processed in the
same manner. The results were compared as indicated. (A) represents part of Figure 3 and is included for easy comparison with (B). Red
represents upregulated expression, and green indicates downregulated expression. (C) The number of overlapping DEGs in different groups of
rat LNCs tested. AA: adjuvant arthritis; DEG: differentially expressed gene; LNC: lymph node cell; Med: medium.
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lism in the pathogenesis of arthritis have revealed var-
ious inflammatory mediators linked to the destruction
of joint tissue. In our study, of 322 DEGs in the early
phase of AA, 11 genes (3.4%) related to oxygen metabo-
lism were upregulated. Three genes encoding different
hemoglobin components were found to be downregu-
lated at the Pk phase, and these genes might be asso-
ciated with severe hypoxia. However, no DEGs related
to oxygen metabolism were found in the Rec phase. We
found that the S100 family members S100A4 (S100a4),
S100A9 (S100a9) and S100A11 (S100a11) were upregu-
lated before the signs of arthritis appeared. Two mem-
bers of this family, S100A8 and S100A9, are particularly
susceptible to oxidative modification [51]. These two
proteins, which are abundantly expressed in neutrophils
and activated macrophages, are associated with various
inflammatory conditions, including RA [51].
As described above, 15 genes were upregulated
throughout the course of AA. In view of the function of
these 15 genes, it was evident that multiple cellular and
biological processes are involved in the progression of
AA. CD163 is expressed in monocytes and macrophages
and subsets of dendritic cells, which play an important
role in the pathogenesis of AA. Costimulatory signals
via Tnfrsf4 (CD134) and antigen presentation via the
major histocompatibility complex class II pathway facili-
tated by the enzyme legumain (encoded by Lgmn) repre-
sent additional important events in the development of
AA. TNF and IFN (as inferred from the expression of
Ifitm1) are proinflammatory cytokines that are known to
p l a yap a t h o g e n i cr o l ei nA A .A d d i t i o n a l l y ,t h eT h 1 7
response (inferred indirectly from the sustained expres-
sion of IL-23R) is another vital event in the disease pro-
cess in AA. The progression of AA also involves
migration (indicated by Ccr4 expression) of inflamma-
tory cells into the target organ, the joint.
Mycobacterial heat shock protein 65-induced gene
expression profile of LEW rats in the preclinical phase of
adjuvant arthritis
The analysis of the Bhsp65-induced gene expression
profile of rats in the Inc phase of AA mostly reinforced
the immune-based and inflammatory nature of AA.
Among the upregulated genes, 56% (23 of 41) were rele-
vant to immune activation, and almost half of them
were genes related to cytokine-cytokine receptor interac-
tions. Upon detailed examination, we observed increased
expression of Il1a (4-fold); Th1-related cytokine and
cytokine receptor or transcription factor, including Ifng
(10-fold), Il12rb2 (4-fold), Tbx21 (2.6-fold) and Stat1
(1.8-fold); Th17-related genes, including CTLA-8 (17-
fold) and Il17f (8-fold); and IL-22 precursor (7-fold). A
notable exception was IL-33, whose expression was
reduced by 60%. In addition, the expression of B-cell-
cycle-activated gene Inhba and complement gene Cfb
was increased. The genes pertaining to chemokines and
their receptors (for example, Cxcl10 and Ccr5) were also
represented in the list of upregulated genes. The expres-
sion of chemokines and their receptors plays a critical
role in regulating cell trafficking and other inflamma-
tion-related events. The Cxcl10 gene showed an eight-
fold increase in expression. CXCL10, which is one of
the ligands for CXCR3, is an IFN-g-induced small pro-
tein secreted by cells in response to IFN-g.C X C L 1 0i s
chemotactic for monocytes, macrophages, neutrophils, T
cells, natural killer cells and immature dendritic cells
[ 5 2 ]a n di sa l s oi n v o l v e di np r o m o t i n gT - c e l la d h e s i o n
to endothelial cells [53]. Of interest, it has been reported
that CXCL10 can be detected at high levels in synovial
tissue [50] as well as the synovial fibroblast cell lines
derived from RA patients [54]. Furthermore, CXCR3
and its ligands are involved in the selective recruitment
of Th1 effector cells into the sites of tissue inflammation
[55,56]. The gene for the receptor for another chemo-
kine, CCR5, was also upregulated after Bhsp65 restimu-
lation. CCR5 is preferentially expressed on Th1 cells,
and CCR5-expressing cells are enriched in the affected
joints of RA patients [49]. Taken together, altered
expression of the genes related to Th1 and Th17
responses is the most predominant change following
Bhsp65 restimulation of LNCs of preclinical arthritis
rats.
A major difference was observed in the expression of
the cytokine genes. Bhsp65-restimulated LNCs revealed
changes in multiple cytokine genes (12 of 61 genes,
19.7%) that showed a high level of expression, in con-
trast to only four cytokine genes (4 of 322 genes, 1.24%)
that showed increased expression in the LNCs of Mtb-
immunized rats tested ex vivo without any Bhsp65 resti-
mulation. The observed differences in DEGs between
Mtb-stimulated LNCs tested ex vivo and Bhsp65-resti-
mulated LNCs in vitro might be attributable to the resti-
mulation of a specific set of genes following reexposure
in vitro to Bhsp65 from among the genes whose expres-
sion was influenced by immunization with Mtb, which
contains multiple antigens.
Gene expression profile of mycobacterial heat shock
protein 65-tolerized LEW rats
We have previously shown that the treatment of LEW
rats with soluble Bhsp65 delivered intraperitoneally led
to the induction of antigen-specific tolerance as well as
significant reduction in the severity of AA [22]. In this
context, we reasoned that the disease-protective effect of
tolerization with Bhsp65 might involve significant down-
regulation of the expression of genes pertaining to mul-
tiple pathways. However, the results of our experiments
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large number of Bhsp65-inducible genes were rather
upregulated in Bhsp65-tolerized rats compared to the
control preclinical arthritis rats. These results show that
antigen-induced tolerance is an active process that upre-
gulates a variety of genes instead of a process that
mostly downregulates gene expression (Table 3). This
finding is contrary to the general impression that tolero-
genic regimens typically shut down immune events.
Understandably, the immune activation processes during
tolerance induction would target pathways that facilitate
regression of inflammatory arthritis, which would
explain the disease-protective effects of the tolerogenic
regimen.
Most of the DEGs (41 of 61, 67.2%) in rats with pre-
clinical AA were also represented among the DEGs of
Bhsp65-tolerized rats (Figure 4C). More interesting than
the higher number of DEGs in Bhsp65-tolerized rats is
the relationship of the selectively upregulated or down-
regulated genes to various disease-related processes in
AA. For example, among the immune response-related
genes, those encoding Th2 response-related molecules,
such as IL-10, IL-33 and IL-15 receptor a chain (IL-
15Ra), were upregulated in Bhsp65-tolerized rats, but
those for IL-10 and IL-15Ra were unaltered in preclini-
cal LEW rats. These results show that the anti-inflam-
matory cytokines play a vital role in the regulation of
arthritis following Bhsp65-induced tolerance, with a
shift of the T-cell phenotype response to anti-inflamma-
tory (Th2) type. Furthermore, no Th17 response-related
genes were upregulated in Bhsp65-tolerized rats, which
is supported by the results of our previous study show-
ing a significant reduction in IL-17 in Bhsp65-tolerized
vs. control rats [22]. These results show that the regula-
tion of arthritis by soluble Bhsp65-induced tolerance
involves comprehensive interactions among different
immune molecules. The increased expression of cell
cycle-related genes in tolerized rats might reflect a rapid
activation of immune cells followed by cell apoptosis,
which then interferes with further immune stimulation
after Mtb immunization. We propose that the testing of
gene expression profiles at the Inc (preclinical) phase of
arthritis might help define the mode of action of the dis-
ease-protective regimen for arthritis by using antigens,
synthetic drugs or natural products [9,22].
As elaborated above, our results derived by microarray
analysis have revealed significant changes in a large
number of genes representing proteins that participate
in multiple pathways, including various immunological
and biochemical pathways (Table 1). At best, microarray
analysis can reveal transcriptional changes in the genes
encoding functional proteins. As the processes of tran-
scription and translation of mRNA are controlled at
multiple levels, and since the final products (the
encoded proteins) can be further modified by posttran-
slational modifications, it is likely that some of the
extrapolations based on mRNA expression might not
materialize at the final protein level. Also, many of the
transcripts on the gene chip used in our study have not
yet been identified. Therefore, a follow-up study of pro-
tein expression profiles in AA is needed to confirm the
extent of the changes implied by our microarray
analysis.
As described above, in this study, we examined the
gene expression profile of the draining LNCs of arthritic
rats and rats subjected to antigen (Bhsp65)-induced tol-
erance. A major proportion of the upregulated genes
were relevant to immune activation (Tables 1 and 3)
and include the genes related to cytokines and cytokine
receptors, cell migration (adhesion molecules, chemo-
kines and chemokine receptors), angiogenesis and
articular damage. Interestingly, most of the genes identi-
fied in the LNCs are also relevant to the arthritis-related
events in the periphery and the target organ, the joints.
The T cells reactive against mycobacterial antigens can
be detected in the spleen, peripheral blood, synovial
fluid and synovial tissue of arthritic animals [7,10,40,41]
as well as in patients with RA [42-44,46,47]. Similarly,
proinflammatory cytokines (for example, IFN-g,T N F - a
and IL-17) can be detected in these body fluids, cells
and tissues [57-59]. Importantly, some of these genes
and proteins can serve as biomarkers (for example,
TNF-a and IL-17) for disease monitoring. Similarly,
chemokines and their receptors, such as CCR5, CXCR7
and CXCL10, can be detected in the leukocytes infiltrat-
ing the synovial tissue in arthritic rats and RA patients
[49,50,52,54,60-62]. In addition, the process of neoangio-
genesis driven by vascular endothelial growth factor
(VEGF) is a hallmark of arthritis in experimental ani-
mals and RA patients [63,64]. These observations vali-
date the significance of our results obtained by testing
LNCs.
Conclusions
Our study is the first to report the gene expression pro-
file of AA. We believe that, together with previous
reports of microarray analysis in other experimental
models of arthritis [65-70], the results of our study sig-
nificantly advance our understanding of the pathogen-
esis of autoimmune arthritis. In particular, by revealing
that the maximal changes in gene expression during the
natural course of AA occur in the preclinical (incuba-
tion phase) of the disease, we have highlighted the sig-
nificance of the preclinical phase of arthritis for further
defining the immunopathogenic events in arthritis as
well as for studying the impact of an immunomodula-
tory regimen such as antigen-induced tolerance. We
have identified a molecular signature consisting of at
Yu et al. Arthritis Research & Therapy 2011, 13:R143
http://arthritis-research.com/content/13/5/R143
Page 13 of 16least 12 arthritis-related genes whose expression was
modulated significantly following Bhsp65-induced toler-
ance (Table 3). These genes encode for CD86, IFN-a-
inducible protein 27- like 1, IL-1b,l y m p h o t o x i n - a,
SOCS3, IL-10, IL-33, IL-17 precursor, IL-17F, IL-22,
CXCR7 and VEGF-A. We believe that the results of
these above-referenced microarray-based studies in ani-
mal models [65-70] and limited studies in RA patients
[68,71,72] provide a strong foundation for further stu-
dies of the preclinical phase of RA and for identifying
reliable biomarkers for the diagnosis, prognosis and
therapeutic evaluation of this debilitating disease.
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